PROGRAM
Thursday 9th October 2025
| Workshop 1 - AI in Medicine Speaker: David Naude |
| Workshop 2 - Updates in Radiation Oncology Speaker: Prof Philip Poortmans & Dr Orit Kaidar-Person |
| Workshop 3 - Perforator Flap Workshop Speaker: Dr Ashutosh Kothari |
| Workshop 4 (Communication) - Hearsay: Have you ever said that? An interactive workshop Speaker: Prof Dame Lesley Fallowfield |
| Lunch - for Workshop Attendees POSTER DISPLAY - AUTHORS PRESENT |
| Welcome to country |
| Session 1 - Hot Topics & Controversies in 2025 NAST and radiotherapy implications 2025 - what is the evidence? Is there a role any more for anthracycline in the treatment of early breast cancer What the HER2? Exploring the limits of Breast Conserving Surgery The challenges and needs of patients facing breast cancer treatment - a patient perspective Q&A panel |
| Session 2 - Wellbeing and Communication KEYNOTE: Impact of language and communication with the well-informed patient Replacement hormone therapy in breast cancer patients AI enhancing productivity at work The reflections of a medical oncologist Q&A panel |
| Social Function - Welcome/Networking Event (Exhibition Area) |
Friday 10th October 2025
| Industry Breakfast Session |
| Industry Breakfast Session |
| Session 3 - Risk Assessment and screening strategies KEYNOTE: genetics - key points to convey to patients An overview of the prospective trials of risk stratified screening including screening protocols Menopause hormone therapy in the high-risk patient with no history of breast cancer A year of experience of live AI reading in NSW BreastScreen OR Real world experience - NSW AI and screening Breast cancer prevention Q&A panel |
| Session 4 - The Neoadjuvant multidisciplinary approach to management of breast cancer- the complexities KEYNOTE: Case Study discussion - the young patient with high risk disease, the timing and sequencing of treatment and oncoplastic surgery Ask the expert panel MDT challenges What does treatment effect look like in lymph nodes Preoperative endocrine therapy as a functional biomarker in ER+ breast cancer Q&A panel |
| Lunch POSTER DISPLAY - AUTHORS PRESENT |
| ASBD AGM |
| Session 5 Rapid fire - Abstracts and oral presentations KEYNOTE: The young premenopausal woman the issues facing fertility, survivorship, pregnancy and genetic implications Q & A 4 x 7 minute oral presentations Q & A 4 x 7 minute oral presentations Q & A |
| Session 6 Innovation and Advances KEYNOTE: AI, Digital Biomarkers - Integration of AI into breast cancer pathology Strategies to reduce re-excision rates including 3D intraoperative specimen tomosynthesis PET Trial and New PET modalities Mainstreaming of genetic testing and the therapeutic value Q&A panel |
| Conference Dinner - QT Hotel Sponsored by |
Saturday 11th October 2025
| Industry Breakfast Session |
| Session 7 Concurrent Sessions 7A Surgery and Radiotherapy - Updates in Management Global perspective on oncoplastic surgical trends Beyond Tc99 for sentinel lymph node mapping: Magtrace, ICG, SAVI Axillary staging update: SNB, TAD & TAS patient selection, safety and technique Debate: Optimal management of residual nodal disease after NACT Q&A panel 7B Medical Oncology - Estrogen receptor positive disease The real world data - experience with CDK4/6 inhibitors in the early and advanced setting What next? What to do after failure of first line endocrine therapy and CDK4/6 inhibitors - the mechanisms of resistance and treatment options The importance of endocrine therapy in the patient with ER positive and HER2-positive disease Are we giving too much or not enough adjuvant ovarian suppression in premenopausal women Q&A panel |
| Session 8 Survivorship KEYNOTE: Key learnings from a real-world survivorship clinic How to manage long term toxicity - bone matters How to manage long term toxicity and outcome -heart matters Lymphoedema & Musculoskeletal issues update Nutrition, diets and supplements - navigating the plethora of information Q&A panel |
Lunch POSTER DISPLAY - AUTHORS PRESENT |
| Session 9 The last word on Controversies Are we overtreating the low-risk cancer? Inflammatory breast cancer - EviQ and surgical options High Breast Density: What now? Fibroepithelial lesions and predicting behaviour Radiotherapy to implant reconstruction and after skin sparing mastectomy |
| Conference Close |
Draft Program - Subject to change
CONTACT US
Impact Events ABN 45 094 598 339
Address: Unit 24, Level 3, 2 Brandon Park Drive, Wheelers
Hill Victoria 3150 Australia
Phone: 1300 061 814 or +61 3 8657 4987 Email: info@impactevents.com.au